Literature DB >> 29601787

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Niklas Mattsson1, Colin Groot2, Willemijn J Jansen3, Susan M Landau4, Victor L Villemagne5, Sebastiaan Engelborghs6, Mark M Mintun7, Alberto Lleo8, José Luis Molinuevo9, William J Jagust4, Giovanni B Frisoni10, Adrian Ivanoiu11, Gaël Chételat12, Catarina Resende de Oliveira13, Karen M Rodrigue14, Johannes Kornhuber15, Anders Wallin16, Aleksandra Klimkowicz-Mrowiec17, Ramesh Kandimalla18, Julius Popp19, Pauline P Aalten3, Dag Aarsland20, Daniel Alcolea8, Ina S Almdahl21, Inês Baldeiras13, Mark A van Buchem22, Enrica Cavedo23, Kewei Chen24, Ann D Cohen25, Stefan Förster26, Juan Fortea8, Kristian S Frederiksen27, Yvonne Freund-Levi28, Kiran Dip Gill18, Olymbia Gkatzima29, Timo Grimmer30, Harald Hampel31, Sanna-Kaisa Herukka32, Peter Johannsen33, Koen van Laere34, Mony J de Leon35, Wolfgang Maier36, Jan Marcusson37, Olga Meulenbroek38, Hanne M Møllergård21, John C Morris39, Barbara Mroczko40, Arto Nordlund16, Sudesh Prabhakar41, Oliver Peters42, Lorena Rami9, Eloy Rodríguez-Rodríguez43, Catherine M Roe39, Eckart Rüther44, Isabel Santana13, Johannes Schröder45, Sang W Seo46, Hilkka Soininen32, Luiza Spiru47, Erik Stomrud48, Hanne Struyfs6, Charlotte E Teunissen49, Frans R J Verhey3, Stephanie J B Vos3, Linda J C van Waalwijk van Doorn50, Gunhild Waldemar27, Åsa K Wallin48, Jens Wiltfang51, Rik Vandenberghe52, David J Brooks53, Tormod Fladby21, Christopher C Rowe5, Alexander Drzezga54, Marcel M Verbeek50, Marie Sarazin55, David A Wolk56, Adam S Fleisher57, William E Klunk25, Duk L Na46, Pascual Sánchez-Juan43, Dong Young Lee58, Agneta Nordberg59, Magda Tsolaki29, Vincent Camus60, Juha O Rinne61, Anne M Fagan39, Henrik Zetterberg62, Kaj Blennow63, Gil D Rabinovici64, Oskar Hansson48, Bart N M van Berckel65, Wiesje M van der Flier66, Philip Scheltens2, Pieter Jelle Visser67, Rik Ossenkoppele68.   

Abstract

INTRODUCTION: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.
METHODS: We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location.
RESULTS: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education. DISCUSSION: The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOE; Age; Alzheimer's disease; Amyloid; CSF; Education; Geographical location; Mild cognitive impairment; PET; Prevalence; Sex; Subjective cognitive decline

Mesh：

Substances：

Year:  2018        PMID： 29601787     DOI： 10.1016/j.jalz.2018.02.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


  26 in total

1.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Authors:  Rik Ossenkoppele; Gil D Rabinovici; Ruben Smith; Hanna Cho; Michael Schöll; Olof Strandberg; Sebastian Palmqvist; Niklas Mattsson; Shorena Janelidze; Alexander Santillo; Tomas Ohlsson; Jonas Jögi; Richard Tsai; Renaud La Joie; Joel Kramer; Adam L Boxer; Maria L Gorno-Tempini; Bruce L Miller; Jae Y Choi; Young H Ryu; Chul H Lyoo; Oskar Hansson
Journal:  JAMA       Date:  2018-09-18       Impact factor: 56.272

Review 2.  The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

Authors:  Giovanni B Frisoni; Daniele Altomare; Dietmar Rudolf Thal; Federica Ribaldi; Rik van der Kant; Rik Ossenkoppele; Kaj Blennow; Jeffrey Cummings; Cornelia van Duijn; Peter M Nilsson; Pierre-Yves Dietrich; Philip Scheltens; Bruno Dubois
Journal:  Nat Rev Neurosci       Date:  2021-11-23       Impact factor: 34.870

3.  CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.

Authors:  Argonde C Van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Richard Batrla-Utermann; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen
Journal:  Neurology       Date:  2020-06-26       Impact factor: 9.910

4.  Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups.

Authors:  Colin Groot; Michel J Grothe; Shubhabrata Mukherjee; Irina Jelistratova; Iris Jansen; Anna Catharina van Loenhoud; Shannon L Risacher; Andrew J Saykin; Christine L Mac Donald; Jesse Mez; Emily H Trittschuh; Gregor Gryglewski; Rupert Lanzenberger; Yolande A L Pijnenburg; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier; Paul K Crane; Rik Ossenkoppele
Journal:  Neuroimage Clin       Date:  2021-04-03       Impact factor: 4.881

Review 5.  Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.

Authors:  Yu Yamazaki; Na Zhao; Thomas R Caulfield; Chia-Chen Liu; Guojun Bu
Journal:  Nat Rev Neurol       Date:  2019-07-31       Impact factor: 44.711

6.  Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population.

Authors:  Yuxia Li; Meimei Kang; Can Sheng; Guanqun Chen; Taoran Li; Jun Wang; Yanning Cai; Rong Wang; Ying Han
Journal:  Neural Plast       Date:  2020-06-06       Impact factor: 3.599

7.  Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment.

Authors:  Tharick A Pascoal; Joseph Therriault; Sulantha Mathotaarachchi; Min Su Kang; Monica Shin; Andrea L Benedet; Mira Chamoun; Cecile Tissot; Firoza Lussier; Sara Mohaddes; Jean-Paul Soucy; Gassan Massarweh; Serge Gauthier; Pedro Rosa-Neto
Journal:  Alzheimers Dement (Amst)       Date:  2020-06-21

Review 8.  Amyloid-β-independent regulators of tau pathology in Alzheimer disease.

Authors:  Rik van der Kant; Lawrence S B Goldstein; Rik Ossenkoppele
Journal:  Nat Rev Neurosci       Date:  2019-11-28       Impact factor: 34.870

9.  Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.

Authors:  Philip S Insel; Oskar Hansson; Niklas Mattsson-Carlgren
Journal:  JAMA Neurol       Date:  2021-02-01       Impact factor: 18.302

10.  The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression.

Authors:  Emma Rhodes; Philip S Insel; Meryl A Butters; Ruth Morin; David Bickford; Duygu Tosun; Devon Gessert; Howie J Rosen; Paul Aisen; Rema Raman; Susan Landau; Andrew Saykin; Arthur Toga; Clifford R Jack; Michael W Weiner; Craig Nelson; Scott Mackin
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.